{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:53:53Z","timestamp":1785840833587,"version":"3.56.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41409-026-02944-8","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:21:05Z","timestamp":1782404465000},"page":"1127-1129","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sequential CLAGE-Ven (cladribine, cytarabine, etoposide, and venetoclax) with reduced-intensity conditioning improves outcomes in patients with refractory acute myeloid leukemia: a prospective phase II study"],"prefix":"10.1038","volume":"61","author":[{"given":"Wen-hui","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chu-ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-ning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-ling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-9447","authenticated-orcid":false,"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5613-1195","authenticated-orcid":false,"given":"Jiong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7965-686X","authenticated-orcid":false,"given":"Ling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"2944_CR1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/CCO.0000000000000780","volume":"33","author":"A Isidori","year":"2021","unstructured":"Isidori A, Ferrara F. The changing landscape for patients with relapsed\/refractory acute myeloid leukaemia. Curr Opin Oncol. 2021;33:635\u201341.","journal-title":"Curr Opin Oncol"},{"key":"2944_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/s41409-017-0028-x","volume":"53","author":"H Ogawa","year":"2018","unstructured":"Ogawa H, Ikegame K, Daimon T, Uchida N, Fukuda T, Kakihana K, et al. Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. Bone Marrow Transplant. 2018;53:478\u201382.","journal-title":"Bone Marrow Transplant"},{"key":"2944_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108:1092\u20139.","journal-title":"Blood"},{"key":"2944_CR4","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3324\/haematol.2016.150326","volume":"102","author":"M Mohty","year":"2017","unstructured":"Mohty M, Malard F, Blaise D, Milpied N, Soci\u00e9 G, Huynh A, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica. 2017;102:184\u201391.","journal-title":"Haematologica"},{"key":"2944_CR5","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00277-020-04074-7","volume":"99","author":"A Le Bourgeois","year":"2020","unstructured":"Le Bourgeois A, Labopin M, Mar\u00e7ais A, de Latour RP, Blaise D, Chantepie S, et al. Sequential allogeneic hematopoietic stem cell transplantation for active refractory\/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol. 2020;99:1855\u201362.","journal-title":"Ann Hematol"},{"key":"2944_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/s41409-022-01639-0","volume":"57","author":"L Wang","year":"2022","unstructured":"Wang L, Gao W, Wang L, Wan M, Jiang J, Hu J. Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial. Bone Marrow Transplant. 2022;57:1004\u20136.","journal-title":"Bone Marrow Transplant"},{"key":"2944_CR7","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1158\/2159-8290.CD-22-1297","volume":"13","author":"S Pei","year":"2023","unstructured":"Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, et al. A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy. Cancer Discov. 2023;13:2032\u201349.","journal-title":"Cancer Discov"},{"key":"2944_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/20406207251319603","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Yin Z, Yao Z, Xu D, Jiang X, Nie X, et al. Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed\/refractory acute myeloid leukemia. Ther Adv Hematol. 2025;16:20406207251319603.","journal-title":"Ther Adv Hematol"},{"key":"2944_CR9","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1200\/JCO.21.02823","volume":"40","author":"TM Kadia","year":"2022","unstructured":"Kadia TM, Reville PK, Wang X, Rausch CR, Borthakur G, Pemmaraju N, et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2022;40:3848\u201357.","journal-title":"J Clin Oncol"},{"key":"2944_CR10","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","volume":"123","author":"P Armand","year":"2014","unstructured":"Armand P, Kim HK, Logan BR, Wang ZW, Alyea EP, Kalaycio ME, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664\u201371.","journal-title":"Blood"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02944-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:36:35Z","timestamp":1785839795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02944-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2944"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02944-8","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The study was approved by the Ethics Committee of Rui Jin Hospital and registered in\n                      \n                      (NCT05870995).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}